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F R O M T H E F A M I L Y P R A C T I C E I N Q U I R I E S N E T W O R K
What is the most effective
beta-blocker 
for heart failure?
■ EVIDENCE-BASED ANSWER
Three beta-blockers—carvedilol, metoprolol, and
bisoprolol—reduce mortality in chronic heart 
failure caused by left ventricular systolic dysfunc-
tion, when used in addition to diuretics and
angiotensin converting enzyme (ACE) inhibitors
(strength of recommendation [SOR]: A, based 
on large randomized placebo-controlled trials). 
No differences in mortality or patient tolerance
have been demonstrated in studies comparing
carvedilol and metoprolol (SOR: B, based on small
head-to-head trials). 
■ EVIDENCE SUMMARY
The Table shows the 5 largest trials of beta-
blockers in systolic dysfunction, including
patients with both ischemic and nonischemic
heart disease. In all trials, the majority of subjects
were taking diuretics and either an ACE inhibitor
or angiotensin receptor blocker.
The Carvedilol Prospective Randomized
Cumulative Survival2 (COPERNICUS) trial,
Metoprolol CR/XL Randomized Intervention Trial
in Heart Failure3 (MERIT-HF), and Cardiac
Insufficiency Bisoprolol Study II4 (CIBIS-II) all
showed similar reductions in mortality in moder-
ately ill patients with heart failure. 
In contrast, the Beta-Blocker Evaluation of
Survival Trial5 (BEST) demonstrated no effect
with bucindolol. This suggests there may be dif-
ferences in effectiveness among beta-blockers
in reducing mortality in heart failure, and that it
would be unwise to assume that protection is a
class effect. We found no meta-analysis that
pooled data on individual drugs for comparison
purposes.
The US Carvedilol trial1 demonstrated a larger
reduction in mortality than that seen in other
beta-blocker trials. However, it had several
methodologic problems: it was a composite of 
4 smaller studies that used exercise tolerance as
the primary endpoint; median duration of data 
collection on subjects was only 6 months; it
included many minimally symptomatic patients;
the actual number of deaths was small (produc-
ing a wide confidence interval); and subjects who
did not survive the run-in phase were excluded
from analysis.6
Three randomized controlled trials have com-
pared carvedilol and metoprolol head-to-head.
The largest7 included 150 subjects with ejection
fractions below 35% who were randomized to 1 of
the 2 drugs and followed for more than 3 years.
Symptom scores and quality of life assessments
were similar in the 2 groups. A trend toward
lower mortality in the carvedilol group did not
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reach statistical significance. Peak oxygen
uptake during exercise was greater in the 
metoprolol group. The carvedilol group had a
statistically greater improvement in ejection
fraction (+10.9 ± 11.0 vs +7.2 ± 7.7 at rest).
The Carvedilol or Metoprolol European Trial
(COMET), a larger head-to-head trial of
carvedilol and metoprolol (N=3029), is ongoing.8
No large studies of older beta-blockers ade-
quately assess mortality in heart failure. One
study of propranolol (N=158) showed a 27%
reduction in mortality in mild heart failure in the
setting of ischemic heart disease.9 A study of
atenolol versus placebo in subjects with ejection
fraction ≤25% from various causes (N=100) was
halted early when atenolol produced a 50%
reduction in worsening heart failure and a 
71% reduction in cardiac hospitalizations.10
A trend toward improved survival was noted but
did not reach statistical significance.  
■ RECOMMENDATIONS FROM OTHERS
We found no guidelines that specifically
endorsed one beta-blocker over another for
heart failure.
Jon O. Neher, MD, Valley Medical Center, Family Practice
Residency, Renton, Wash; Sarah Safranek, MLIS,
University of Washington Health Sciences Libraries, Seattle
Selected trials of beta-blockers for systolic dysfunction
Mortality Mean duration
reduction 95% Statistically of follow-up
Study Drug N (%) CI (%) significant? NNT (months)
US Carvedilol1 Carvedilol 1094 (65) 39–80 Yes 22 6.5
COPERNICUS2 Carvedilol 2289 (35) 19–48 Yes 14 10.4
MERIT-HF3 Metoprolol 3991 (34) 19–46 Yes 26 12
CIBIS II4 Bisoprolol 2647 (34) 19–47 Yes 18 15.6
BEST5 Bucindolol 2708 (9) –0.2–22 No — 24
CI, confidence interval; NNT, number needed to treat
TA B L E
■ CLINICAL COMMENTARY
To provide the best care, we must go beyond
the conventional ACE inhibitor and diuretic
therapy for congestive heart failure patients.
Adding 1 of the 3 beta-blockers (carvedilol,
metoprolol, or bisoprolol), as recommended
above, will further improve the survival rates
and decrease hospitalization rates. 
Remember these pearls when using beta-
blockers in congestive heart failure:
• Do not start therapy until the patient’s fluid
status has been stable for at least 1 month
• Avoid using in patients with bronchospastic
disease, symptomatic bradycardia, or
advanced heart blockage
• Start with low doses and titrate up slowly as
tolerated every 2 weeks to the recommend-
ed target range of the beta-blocker chosen 
• Decrease the dose if significant bradycardia
or atrioventricular block occurs
• Let your patients know that it may take sev-
eral months of beta-blocker therapy to
obtain the protective benefits.
If you encounter difficulties with titration or
don’t feel comfortable initiating beta-blocker
therapy, consult your cardiologist for help.
Fred Grover, Jr, MD, University of Colorado Health
Sciences Center, Denver
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Evidence shows that the combination of diuretics, ACE inhibitors, and 1 of 3 beta-blockers—carvedilol,
metoprolol, bisoprolol—is more effective than just diuretics plus ACE inhibitors. The clinical effect of their
combined actions is reduced workload on the failing heart.
Chronic heart failure
Complementary actions of diuretics, ACE inhibitors, and beta blockers
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Diuretics increase excretion
of sodium and water and
thereby decrease plasma
volume, through glomerular
filtration or secretion across
the proximal tubule.
Beta-blockers aid the failing heart 
in several ways:
• Slow the heart rate
• Reduce the myocardial contractility
• Increase vasodilation 
(carvedilol, metoprolol)
Through dilation of peripheral
arteries and veins, ACE inhibitors
enchance left ventricular function
by reducing filling pressure and
systemic resistance.
